COMMUNIQUÉS West-GlobeNewswire
-
Prenetics’ IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services
05/12/2024 -
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
05/12/2024 -
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
05/12/2024 -
Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
05/12/2024 -
Branded Legacy, Inc. Strengthens Biotech Leadership, Focuses on Expansion, and Advances Strategic Rebranding
05/12/2024 -
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
05/12/2024 -
STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
05/12/2024 -
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Products
05/12/2024 -
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
05/12/2024 -
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
05/12/2024 -
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
05/12/2024 -
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
05/12/2024 -
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
05/12/2024 -
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
05/12/2024 -
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
04/12/2024 -
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
04/12/2024 -
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/12/2024 -
Monthly information on share capital and company voting rights
04/12/2024 -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/12/2024
Pages